Doximity (NYSE:DOCS) Price Target Cut to $26.00 by Analysts at Mizuho

Doximity (NYSE:DOCS) had its price target decreased by Mizuho from $34.00 to $26.00 in a report published on Thursday, MarketBeat.com reports. Mizuho currently has a neutral rating on the stock.

DOCS has been the subject of several other research reports. Truist Financial reiterated a “hold” rating and issued a $29.00 target price (down from $37.00) on shares of Doximity in a research note on Monday, April 20th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $44.00 target price on shares of Doximity in a research note on Monday, March 9th. Robert W. Baird reiterated a “neutral” rating and issued a $18.00 target price (down from $40.00) on shares of Doximity in a research note on Thursday. Barclays reduced their target price on shares of Doximity from $63.00 to $38.00 and set an “overweight” rating for the company in a research note on Wednesday, February 11th. Finally, Jefferies Financial Group cut shares of Doximity from a “buy” rating to a “hold” rating and reduced their target price for the company from $51.00 to $19.00 in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $30.62.

Doximity Trading Down 23.3%

Shares of NYSE:DOCS opened at $17.94 on Thursday. The firm has a market capitalization of $3.31 billion, a P/E ratio of 18.12, a P/E/G ratio of 1.66 and a beta of 1.36. The company has a 50-day simple moving average of $24.09. Doximity has a 52-week low of $17.15 and a 52-week high of $76.51.

Doximity declared that its Board of Directors has approved a share repurchase program on Thursday, February 5th that allows the company to buyback $500.00 million in shares. This buyback authorization allows the company to buy up to 8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Transactions at Doximity

In other Doximity news, Director Kira Scherer Wampler sold 9,000 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $26.06, for a total transaction of $234,540.00. Following the completion of the transaction, the director owned 19,839 shares in the company, valued at $517,004.34. This trade represents a 31.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,427 shares of the firm’s stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $21.09, for a total transaction of $51,185.43. Following the transaction, the insider owned 86,705 shares of the company’s stock, valued at approximately $1,828,608.45. This represents a 2.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 18,055 shares of company stock valued at $456,061. Corporate insiders own 31.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DOCS. Vanguard Group Inc. raised its stake in shares of Doximity by 4.1% in the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock valued at $588,281,000 after acquiring an additional 518,916 shares during the last quarter. Aubrey Capital Management Ltd bought a new position in shares of Doximity in the third quarter valued at approximately $4,572,000. UBS Group AG raised its stake in shares of Doximity by 26.5% in the fourth quarter. UBS Group AG now owns 680,260 shares of the company’s stock valued at $30,122,000 after acquiring an additional 142,408 shares during the last quarter. Blair William & Co. IL raised its stake in shares of Doximity by 1,990.7% in the third quarter. Blair William & Co. IL now owns 362,740 shares of the company’s stock valued at $26,534,000 after acquiring an additional 345,390 shares during the last quarter. Finally, William Blair Investment Management LLC raised its stake in shares of Doximity by 11.7% in the third quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock valued at $426,404,000 after acquiring an additional 609,775 shares during the last quarter. Institutional investors own 87.19% of the company’s stock.

Doximity News Summary

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported adjusted EPS of $0.26, ahead of one analyst estimate, and revenue rose 5.1% year over year to $145.37 million, showing the core business is still growing. Doximity Earnings Report
• Positive Sentiment: Commentary around AI adoption and customer growth suggests Doximity’s platform remains engaged with clinicians, which could support longer-term monetization. Zacks Coverage
• Neutral Sentiment: The company maintained strong profitability metrics, including a 23.84% return on equity and 37.54% net margin, but those figures were overshadowed by weaker near-term outlook commentary. Fiscal Q4 Earnings Snapshot
• Negative Sentiment: Doximity missed the broader analyst consensus on EPS, which disappointed traders looking for a stronger earnings beat. Doximity Lags Q4 Earnings Estimates
• Negative Sentiment: Most importantly, fiscal 2027 revenue guidance came in below Wall Street expectations, reinforcing concerns that growth is slowing while AI-related investment is pressuring margins. Doximity Q4 2026 Earnings Call Transcript
• Negative Sentiment: Multiple analysts cut price targets after the report, including JPMorgan, Truist, BMO Capital, Mizuho, and Needham, adding to the negative sentiment around the stock. Analyst Target Cuts
• Negative Sentiment: Unusual put-option buying and an insider share sale added to the cautious tone, even though the insider transaction was part of a pre-arranged trading plan. Insider Trade Disclosure

Doximity Company Profile

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.